Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment.

Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Abstract Text:

Haruhiko Nukaya,Tomoyoshi Ohno,Kenji Sakakibara,Atunaga Kato,Izumi Hasegawa,Seijiro Matunaga,Masayuki Endo,Yoshito Tanaka,Noboru Hirashima,Yasuhito Tanaka,Etsuro Orito,Takashi Joh,Masashi Mizokami,

Aims: Infection with hepatitis viruses following blood exposure accidents, such as needle stick injuries, is a serious issue for medical staff. In particular, although accidental exposure to hepatitis C virus (HCV) occurs frequently, postexposure prophylactic measures have not been established yet. In this study we investigate the efficacy of recombinant alpha-2b interferon (IFN) as a single, 10 MU intramuscular injection for preventing transmission. Methods: 264 incidents of accidental blood to HCV antibody-positive blood, occurring between 1993 and 2003 in the Social Insurance Chukyo Hospital, were surveyed. Accident reports, which described in detail the circumstances and the presence or absence of infectious disease in the blood, and accidental exposure to HCV antibody-positive blood was investigated. Results: Pre-emptive IFN treatment was given in 115 out of 157 cases occurring between 1993 and 1998. One case developed acute HCV. Phylogenetic analysis provided evidence that the accident caused the infection and the patient was cured by immediate IFN therapy. Between 1999 and 2003, the exposed were in principle followed-up without IFN treatment; IFN treatment was only given when requested. As a result, IFN was given in 14 of 107 cases. During this period, no transmission was observed. Conclusion: Taken together, the benefits of pre-emptive IFN treatment were considered unremarkable and a follow-up without treatment, or immediate IFN therapy after confirmation of the onset, was recommended.

Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Publishing Authors By Initials

H Nukaya,T Ohno,K Sakakibara,A Kato,I Hasegawa,S Matunaga,M Endo,Y Tanaka,N Hirashima,Y Tanaka,E Orito,T Joh,M Mizokami,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Hepatology research : the official journal of the

VOLUME: 37

Page Numbers: 179-85

Journal Abbreviation: Hepatol. Res.

ISSN: 1386-6346

DAY: 16

MONTH: Mar

YEAR: 2007

Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9711801

Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment.

AFFILIATION: Department of Gastroenterology, Social Insurance Chukyo Hospital, Nagoya, Japan.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hepatol Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment Related Publications

• A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C.
• Accidental exposure to HCV antibody-positive blood in hospital and pre-emptive one-shot interferon alpha-2b treatment.
• Characteristics of hepatitis B virus genotype G coinfected with genotype H in chimeric mice carrying human hepatocytes.
• Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in arctic indigenous populations.
• Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion.
• Development and public release of a comprehensive hepatitis virus database.
• Differences of HBV genotypes and hepatocellular carcinoma in Asian countries.
• Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan.
• Field spread of a diffracted Gaussian beam through a circular aperture.
• Hepatitis B caused by a hepatitis B surface antigen escape mutant.
• Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan.
• Impact of daily high-dose IFNalpha-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels.
• Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.
• Long-term efficacy of preoperative radiotherapy for locally advanced low rectal cancer.
• Pelvic drainage for anterior resection revisited: use of drains in anastomotic leaks.
• Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells.
• Retroposition of the mandible in complete denture wearers.
• Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis.
• Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia.
• Transmission of hepatitis B virus (HBV) genotypes among Japanese immigrants and natives in Bolivia.
• Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism.
• Tympanic membrane temperature in a patient with vertigo.
• Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
• When should "i" consider a new hepatitis B virus genotype?
• [Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay]
• [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects]